Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALONZO E JONES

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1952389991
CMS profile
418907
Location
COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$830.59

35 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $830.59 35

By paying entity

PY2024 · entire year · sorted by reported total

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALONZO E JONES

NPI 1952389991 · CMS profile ID 418907

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

COLUMBUS, GA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1952389991?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALONZO E JONES, NPI 1952389991, CMS profile ID 418907. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1952389991?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALONZO E JONES, NPI 1952389991, CMS profile ID 418907. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1952389991?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALONZO E JONES, NPI 1952389991, CMS profile ID 418907, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–35 of 35 matching records. This page contains 35 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1952389991?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

35 matching records · $830.59 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 35 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–35 of 35.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $6.8312/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080559535 CMS
Novartis Pharmaceuticals Corporation $13.4511/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087059276 CMS
E.R. Squibb & Sons, L.L.C. $14.5611/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531952 CMS
Merck Sharp & Dohme LLC $22.5111/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141706764 CMS
SCPHARMACEUTICALS INC. $15.3810/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132305908 CMS
AstraZeneca Pharmaceuticals LP $16.2810/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105247585 CMS
E.R. Squibb & Sons, L.L.C. $17.3409/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531897 CMS
Merck Sharp & Dohme LLC $19.8709/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141870653 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.1809/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1118248141 CMS
AstraZeneca Pharmaceuticals LP $15.6709/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105899964 CMS
CVRx, Inc. $25.6808/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132814737 CMS
Novo Nordisk Inc $21.4108/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097246137 CMS
E.R. Squibb & Sons, L.L.C. $17.4808/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531870 CMS
E.R. Squibb & Sons, L.L.C. $0.5008/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531878 CMS
PFIZER INC. $15.9107/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131854511 CMS
E.R. Squibb & Sons, L.L.C. $2.1507/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531874 CMS
PFIZER INC. $17.6007/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131776909 CMS
AstraZeneca Pharmaceuticals LP $18.3106/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104460844 CMS
Merck Sharp & Dohme LLC $18.1706/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141706600 CMS
E.R. Squibb & Sons, L.L.C. $8.9705/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531826 CMS
Abbott Laboratories $18.3905/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125353874 CMS
E.R. Squibb & Sons, L.L.C. $17.7505/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531802 CMS
Inspire Medical Systems, Inc. $118.8505/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148063556 CMS
PFIZER INC. $13.9305/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131471759 CMS
Inspire Medical Systems, Inc. $45.8004/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1148063552 CMS
E.R. Squibb & Sons, L.L.C. $109.5804/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531806 CMS
CVRx, Inc. $23.5604/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132814735 CMS
Merck Sharp & Dohme LLC $18.0904/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141706596 CMS
E.R. Squibb & Sons, L.L.C. $16.5904/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531786 CMS
Baxter Healthcare $41.0403/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120626294 CMS
Novo Nordisk Inc $19.8702/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096731418 CMS
Innovation Technologies Inc $20.2502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130821528 CMS
E.R. Squibb & Sons, L.L.C. $13.0802/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101531755 CMS
Merck Sharp & Dohme LLC $17.0201/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141706598 CMS
Innovation Technologies Inc $17.5401/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1130821526 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $559.09 41
PY2020 $448.72 36
PY2021 $570.20 38
PY2022 $625.57 30
PY2023 $1,200.24 49
PY2024 $830.59 35
PY2025 $831.80 31

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2023 Principal investigator $24,416.95 19
PY2022 Principal investigator $89,144.80 16
PY2021 Principal investigator $140,262.94 64
PY2020 Recipient $20,304.24 16
PY2020 Principal investigator $97,368.42 58
PY2019 Recipient $20,304.24 16
PY2019 Principal investigator $57,349.01 39

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $11,170.69 12/31/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE COLUMBUS CARDIOLOGY ASSOCIATES
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 848740463
Principal investigator 1 Merck Sharp & Dohme Corporation $1,910.80 12/31/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE COLUMBUS CARDIOLOGY ASSOCIATES
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 848740465
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,250.00 12/09/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789152543
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,060.00 12/07/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789148003
Principal investigator 1 Merck Sharp & Dohme Corporation $20,000.00 11/24/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE COLUMBUS CARDIOLOGY ASSOCIATES
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat,MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction No dispute reported 06/30/2026 848740375
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,875.00 11/09/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789152327
Principal investigator 1 ARRAY BIOPHARMA INC $75.00 10/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832660169
Principal investigator 1 ARRAY BIOPHARMA INC $2,500.00 10/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832660671
Principal investigator 1 ARRAY BIOPHARMA INC $1,500.00 10/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832660681
Principal investigator 1 ARRAY BIOPHARMA INC $500.00 10/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832660690
Principal investigator 1 ARRAY BIOPHARMA INC $110.00 10/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832662135
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,378.00 09/28/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789149682
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,029.00 09/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789151649
Principal investigator 1 Vifor (International) Ltd. $1,012.54 09/16/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520575
Principal investigator 1 Vifor (International) Ltd. $1,012.54 09/16/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520585
Principal investigator 1 Vifor (International) Ltd. $1,546.24 09/16/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520771
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $159.00 09/07/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789144257
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $159.00 09/07/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789149283
Principal investigator 1 Vifor (International) Ltd. $952.85 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519695
Principal investigator 1 Vifor (International) Ltd. $1,162.08 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519715
Principal investigator 1 Vifor (International) Ltd. $1,162.08 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519725
Principal investigator 1 Vifor (International) Ltd. $1,197.76 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519735
Principal investigator 1 Vifor (International) Ltd. $1,197.76 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519745
Principal investigator 1 Vifor (International) Ltd. $1,197.76 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519757
Principal investigator 1 Vifor (International) Ltd. $1,197.76 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519767
Principal investigator 1 Vifor (International) Ltd. $1,429.62 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520001
Principal investigator 1 Vifor (International) Ltd. $2,925.10 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520021
Principal investigator 1 Vifor (International) Ltd. $2,925.10 09/02/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840520031
Principal investigator 1 ARRAY BIOPHARMA INC $1,336.50 09/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832905057
Principal investigator 1 ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $2,000.00 09/01/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
BMAD No dispute reported 06/30/2026 793079965
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $245.00 08/30/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789142875
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,560.00 08/30/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789146545
Principal investigator 1 ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10,320.00 08/25/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
BMAD No dispute reported 06/30/2026 793079963
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,414.00 07/28/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789151891
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $728.00 07/26/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789152121
Principal investigator 1 Vifor (International) Ltd. $1,197.76 07/22/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519135
Principal investigator 1 Vifor (International) Ltd. $1,546.24 07/22/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840519145
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,881.00 06/23/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789142103
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,797.00 06/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789145421
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,131.00 06/02/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789145999
Principal investigator 1 Amgen Inc. $1,580.00 05/26/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
GALACTIC - HF No dispute reported 06/30/2026 830982003
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,762.00 05/26/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789141299
Principal investigator 1 ARRAY BIOPHARMA INC $750.00 05/21/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832732147
Principal investigator 1 Vifor (International) Ltd. $156.00 05/20/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840517589
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,750.00 04/26/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789151364
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,474.00 04/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789150393
Principal investigator 1 Amgen Inc. $275.00 03/31/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE
GALACTIC - HF No dispute reported 06/30/2026 830982001
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $4,596.00 03/24/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789148437
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,554.00 03/22/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789150735
Principal investigator 1 ARRAY BIOPHARMA INC $110.00 03/04/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832816585
Principal investigator 1 ARRAY BIOPHARMA INC $500.00 03/04/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832878289
Principal investigator 1 ARRAY BIOPHARMA INC $75.00 03/04/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832923657
Principal investigator 1 Vifor (International) Ltd. $400.00 03/04/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840516091
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,750.00 03/03/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789144813
Principal investigator 1 Vifor (International) Ltd. $1,197.76 02/25/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INSTITUTE LLC_GR-USUSD-0405FI_USD_INC Research, LLC
PAT-CR-302 No dispute reported 06/30/2026 840515897
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,953.00 02/24/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789147037
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $300.00 02/24/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789151055
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $5,571.00 02/22/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789148871
Principal investigator 1 ARRAY BIOPHARMA INC $50.00 02/13/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832736871
Principal investigator 1 ARRAY BIOPHARMA INC $50.00 02/13/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832921867
Principal investigator 1 ARRAY BIOPHARMA INC $156.00 02/10/2021 Non-covered Recipient Entity
COLUMBUS REGIONAL RESEARCH INST
A PHASE 3 MULTINATIONAL RANDOMIZED PLACEBOCONTROLLED STUDY OF ARRY371797 PF07265803 IN PATIENTS WITH SYMPTOMATIC DILATED CARDIOMYOPATHY DUE TO A LAMIN AC GENE MUTATION No dispute reported 06/30/2026 832783735
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,122.00 01/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789143595
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $825.00 01/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
A multicenter randomized double-blind parallel-group placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction = 40% (LVEF = 40%) No dispute reported 06/30/2026 789147523
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,554.00 01/21/2021 Non-covered Recipient Entity
Columbus Regional Research Institute
Multicenter randomized placebo controlled double-blind parallel group dose-finding Phase 2 study to evaluate the efficacy and safety of BAY 2433334 in patients following an acute myocardial infarction No dispute reported 06/30/2026 789150047